NX-3911

Advertisement

cGxPJobs Banner

Dianthus Unveils DNTH312 Dual-Target Autoimmune Therapy

NEW YORK and WALTHAM, Mass., August 4, 2026 Dianthus Therapeutics, Inc. announced the launch of DNTH312, an internally developed...

By cGxPwire Editor
August 5, 2026

Read More

Nurix and Sanofi Advance Oral STAT6 Degrader into Phase 1 Clinical Development

BRISBANE, Calif., August 4, 2026 Nurix Therapeutics, Inc. announced it has earned a $10 million development milestone payment after...

By cGxPwire Editor
August 5, 2026

Read More

Advertisement

cGxPJobs

Directory